基于干扰素应答指导治疗策略对HBeAg阳性乙型肝炎的疗效

Efficacy of interferon-based response-guided therapy for the HBeAg-positive hepatitis B

HBeAg持续阳性是乙型肝炎进展为肝硬化、肝癌的危险因素之一，而目前常规治疗方案的总体HBeAg转换率并不理想，能获得停药后持续应答的患者比率较低。基于IFN应答指导治疗策略来提高血清学应答率是目前研究的热点。本综述重点阐述不同的基于IFN应答指导治疗策略对HBeAg阳性乙型肝炎的疗效及安全性。

HBeAg-positive hepatitis B is one of the risk factors progressing to liver cirrhosis and liver cancer. At present, the conversion rate of HBeAg in conventional therapy is not ideal and percentage of patients who can get sustained response after drug withdrawal is low. To increase response rates by response-guided therapy is the focus of current research. The effect and safety of different interferon-based response-guided therapeutic strategies for HBeAg-positive hepatitis B are reviewed in this article.